Drug
Asp9521
Asp9521: highest development phase Phase 1/2, developed by Astellas. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Astellas
Trials
| Drug | Phase | Indication |
|---|---|---|
| ASP9521 NCT01352208 | Phase 1/2 | Castrate Resistant Prostate Cancer |
Latest
No recent events.
Follow Asp9521 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.